The Denning Issues Test, Version 2 (DIT2), updates dilemmas and items, shortens the original Defining Issues Test (DIT1) of moral judgment, and purges fewer participants for doubtful response reliability. DIT1 has been used for over 25 years. DIT2 makes 3 changes: in dilemmas and items, in the algorithm of indexing, and in the method of detecting unreliable participants. With all 3 changes, DIT2 is an improvement over DIT1. The validity criteria for DIT2 are (a) significant age and educational differences among 9th graders, high school graduates, college seniors, and students in graduate and professional schools; (b) prediction of views on public policy issues (e.g., abortion, religion in schools, rights of homosexuals, women's roles); (c) internal reliability; and (d) correlation with DIT1. However, the increased power of DIT2 over DIT1 is primarily due to the new methods of analysis (a new index called N2, new checks) rather than to changes in dilemmas, items, or instructions. Although DIT2 presents updated dilemmas and smoother wording in a shorter test (practical improvements), the improvements in analyses account for the validity improvements.
Kohlberg's LegacyForemost in Larry Kohlberg's legacy is his modelling of openness to new developments and possibilities. When he was rst formulating his theory of moral development, the work of Jean Piaget was coming to the attention of American psychologists (e.g. Flavell, 1963), and the work of John Rawls in moral philosophy (1971) was recognised as a new way for moral philosophy to say something signi cant (beyond clarifying moral language) about normative ethics. Kohlberg's fusion of Piaget and Rawls excited many researchers because of its interdisciplinary approach (taking seriously the questions and contributions of developmental psychology and of normative ethics), and because it addressed issues of the day (e.g. what is social justice?). Recall that in the 1960s and 1970s the US Civil Rights movement, the Vietnam War and the Watergate Scandal were all controversial issues that divided
Chronic tissue ischemia due to defective vascular perfusion is a hallmark feature of peripheral artery disease for which minimal therapeutic options exist. We have reported that sodium nitrite therapy exerts cytoprotective effects against acute ischemia/reperfusion injury in both heart and liver, consistent with the model of bioactive NO formation from nitrite during ischemic stress. Here, we test the hypothesis that chronic sodium nitrite therapy can selectively augment angiogenic activity and tissue perfusion in the murine hind-limb ischemia model. Various therapeutic doses (8.25-3,300 g/kg) of sodium nitrite or PBS were administered. Sodium nitrite significantly restored ischemic hind-limb blood flow in a timedependent manner, with low-dose sodium nitrite being most effective. Nitrite therapy significantly increased ischemic limb vascular density and stimulated endothelial cell proliferation. Remarkably, the effects of sodium nitrite therapy were evident within 3 days of the ischemic insult demonstrating the potency and efficacy of chronic sodium nitrite therapy. Sodium nitrite therapy also increased ischemic tissue nitrite and NO metabolites compared to nonischemic limbs. Use of the NO scavenger carboxy PTIO completely abolished sodium nitrite-dependent ischemic tissue blood flow and angiogenic activity consistent with nitrite reduction to NO being the proangiogenic mechanism. These data demonstrate that chronic sodium nitrite therapy is a recently discovered therapeutic treatment for peripheral artery disease and critical limb ischemia.wound healing ͉ endothelial cell ͉ nitric oxide ͉ peripheral artery disease ͉ tissue perfusion
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.